Drugs Made In America Acquisition II Corp. (DMII) Common Equity (2024 - 2026)

Drugs Made In America Acquisition (DMII) has reported Common Equity for 3 consecutive years, with -$17.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity changed N/A year-over-year to -$17.9 million in Q2 2026; TTM through Jun 2026 was -$17.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$17.8 million, down 15128.73% from the prior year.
• Common Equity was -$17.9 million for Q2 2026 at Drugs Made In America Acquisition, down from -$17.8 million in the prior quarter.
• Over five years, Common Equity peaked at -$116719.0 in Q4 2024 and troughed at -$17.9 million in Q2 2026.
• A 3-year average of -$13.3 million and a median of -$17.5 million in 2025 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 15128.73% in 2025, down 15128.73% in 2025.
• Over 3 years, Common Equity stood at -$116719.0 in 2024, then slumped by 15128.73% to -$17.8 million in 2025, then dropped by 0.85% to -$17.9 million in 2026.
• The last three Common Equity figures came in at -$17.9 million (Q2 2026), -$17.8 million (Q4 2025), and -$17.3 million (Q3 2025), per Business Quant data.